XORTX Therapeutics Inc (TSE:XRTX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
XORTX Therapeutics Inc., a pharmaceutical company specializing in treatments for kidney disease, has refiled its management’s discussion and analysis reports for 2023 and the first half of 2024 after a review by the Alberta Securities Commission. The updated filings include a complete definition of Disclosure Controls and Procedures and more detailed breakdowns of funding usage and estimated costs for the company’s product candidates.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
